# Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy

> **NCT02181335** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 684 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Respimat® Budesonide low dose
- **DRUG:** Respimat® Budesonide high dose
- **DRUG:** Turbohaler® Budesonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02181335
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-10
- **Primary completion:** 2001-06
- **Final completion:** —
- **Target enrollment:** 684 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181335, "Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02181335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*